Switching from donepezil tablets to rivastigmine transdermal patch in alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 24, Issue 3, 2009, Pages 267-275

  Sadowsky, Carl H ^a,b,e   Dengiz, Alan ^c   Olin, Jason T ^c,d   Koumaras, Barbara ^d   Meng, Xiangyi ^d   Brannan, Stephen ^e  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b Saint Joseph Mercy Health System   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d TAKEDA PHARMACEUTICALS   (United States)

^e Premiere Research Institute   (United States)

Author keywords

Alzheimer's disease; Clinical trial; Donepezil; Rivastigmine; Switching; Transdermal patch

Indexed keywords

DONEPEZIL; MEMANTINE; METOPROLOL; RIVASTIGMINE;

ADULT; AGED; AGITATION; ALZHEIMER DISEASE; APPLICATION SITE REACTION; ARTICLE; ATRIOVENTRICULAR BLOCK; BODY WEIGHT; BRADYCARDIA; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FEMALE; HALLUCINATION; HEARING IMPAIRMENT; HEART BUNDLE BRANCH BLOCK; HEART RIGHT BUNDLE BRANCH BLOCK; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SOMNOLENCE; STUPOR; T WAVE; TREATMENT DURATION; VAGINA TUMOR; VOMITING;

EID: 68149107608     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/1533317509333037     Document Type: Article

References (20)

1. Doody RS, Stevens JC, Beck C., et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 ; 56: 1154-1166.
2. Geldmacher DS Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care. Prim Care Companion J Clin Psychiatry. 2007 ; 9: 113-121.
3. Small G., Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin. 2007 ; 23: 2705-2713.
4. Ryan AA Medication compliance and older people: a review of the literature. Int J Nurs Stud. 1999 ; 36: 153-162.
5. Gauthier S., Emre M., Farlow MR, Bullock R., Grossberg GT, Potkin SG Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003 ; 19: 707-714. (Pubitemid 37466140)
6. Farlow MR, Miller ML, Pejovic V. Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord. 2008 ; 25: 408-422.
7. Auriacombe S., Pere JJ, Loria-Kanza Y., Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 2002 ; 18: 129-138. (Pubitemid 34665750)
8. Emre M. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int J Clin Pract Suppl. 2002 ;(127). 64-72.
9. Sadowsky CH, Farlow MR, Atkinson L., et al. Switching from donepezil to rivastigmine is well tolerated: results of an open-label safety and tolerability study. Prim Care Companion J Clin Psychiatry. 2005 ; 7: 43-48.
10. Corey-Bloom J., Anand R., Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Pyschopharmacol. 1998 ; 1: 55-65.
11. Rosler M., Anand R., Cicin-Sain A., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 ; 318: 633-638.
12. Winblad B., Grossberg G., Frolich L., et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007 ; 69 (4 suppl 1). S14 - S22.
13. Winblad B., Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry. 2007 ; 22: 485-491.
14. Shua-Haim J., Smith JM, Amin S. Crossover results of donepezil (Aricept) to rivastigmine (Exelon) in Alzheimer's disease patients: a two-month prospective study. Poster presented at: the Annual Scientific Meeting of the American Geriatric Society ; May 9-13, 2001 ; Chicago, Ill (P329).
15. Shua-Haim J., Smith J., Amin S. Results of switching from donepezil (Aricept) to rivastigmine (Exelon) in Alzheimer's disease patients: a two-month prospective study. Poster presented at: the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy ; April 3-6, 2002. Geneva, Switzerland (A43A).
16. Figiel GS, Sadowsky CH, Strigas J., Koumaras B., Meng X., Gunay I. Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study. Prim Care Companion J Clin Psychiatry. 2008 ; 10: 291-298.
17. Cummings JL Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry. 2003 ; 11: 131-145.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR«) 1994.
19. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 ; 34: 939-944.
20. Folstein MF, Folstein SE, McHugh PR ''Mini-mental state''. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 ; 12: 189-198.